Tag Archive for: BRCA2

ASTX295 + Olaparib: A Targeted Strategy for BRCA2‑Mutant, TP53‑Wild‑Type Cancers

ASTX295 is an experimental cancer drug that works by turning on a powerful tumor‑suppressor protein called p53 in cancer cells that still have a normal version of the gene TP53. In many cancers, p53 is not broken but is kept switched off by another protein called MDM2, which constantly tags p53 for destruction. ASTX295 blocks […]

Complete Response to Pembrolizumab in a Metastatic, Castration‑Resistant Prostate Cancer Survivor

A remarkable case published in Annals of Internal Medicine: Clinical Cases highlights a man with metastatic, castration‑resistant prostate cancer who achieved a complete and durable response to pembrolizumab after exhausting multiple standard therapies. The patient had previously received abiraterone‑based treatment followed by chemotherapy, and then olaparib, all of which he had progressed on, leaving him […]

BRCAAway OS Update: Abiraterone + Olaparib Extends Survival by 5 Years in HRRm mCRPC

The BRCAAway trial brings strong new data on treating metastatic castration-resistant prostate cancer, or mCRPC, in patients with specific DNA repair defects known as homologous recombination repair mutations, or HRRm. This phase 2 study tested abiraterone alone, olaparib alone, or the two drugs together as first-line therapy. It focused on patients with germline or somatic […]

Genomic Alterations and LuPSMA Outcomes in mCRPC: A Prognostic Insight

Genomic alterations like TP53, PTEN, and RB1 mutations are prevalent in metastatic castration-resistant prostate cancer (mCRPC), yet their impact on response to 177Lu-PSMA-617 (LuPSMA, Pluvicto) radioligand therapy remains underexplored. A recent retrospective study published in the Journal of Nuclear Medicine analyzed 72 mCRPC patients treated with at least one cycle of LuPSMA between October 2022 […]

SPR1020: a Promising PARP1-Selective Inhibitor in Advanced Solid Tumors (Including mCRPC)

A  first-in-human Phase 1/2 trial of SPR1020, a highly selective PARP1 inhibitor, dosed its inaugural patient, igniting hope for patients with advanced solid tumors harboring DNA repair deficiencies. This open-label, multicenter study employs a classic 3+3 dose-escalation design to pinpoint the recommended Phase II dose or maximum tolerated dose, transitioning seamlessly into expansion cohorts tailored […]

AMPLITUDE Trial Update: Niraparib Plus Abiraterone Shows Promise for HRR-Altered Metastatic Prostate Cancer